# OnCo record capecitabine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/capecitabine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "capecitabine" ;
  schema:name "Capecitabine"@en ;
  schema:description "Capecitabine (Xeloda) is a tablet form of the chemotherapy fluorouracil. It is a backbone of treatment for bowel cancer and a standard option in advanced breast cancer."@en ;
  schema:url <https://onco.cc/drugs/capecitabine/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Capecitabine> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=capecitabine>, <https://www.cancer.gov/about-cancer/treatment/drugs/capecitabine>, <https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda>, <https://doi.org/10.1200/JCO.24.01118>, <https://www.nice.org.uk/guidance/ng85/chapter/Recommendations> ;
  onco:status "approved" ;
  onco:tag "nci-list", "generic" ;
  onco:modality "Oral fluoropyrimidine prodrug (antimetabolite)" ;
  schema:alternateName "Xeloda" ;
  onco:approval "US 1998: Metastatic breast cancer after anthracycline and taxane; later adjuvant and metastatic colorectal cancer, rectal chemoradiotherapy", "EU 2001: Colorectal, gastric and breast cancer" ;
  onco:acceleratedApproval "US 1998-04-30: Metastatic breast cancer resistant to paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and further anthracycline therapy is contraindicated" ;
  onco:acceleratedApprovalConfirmed "US 2001-09-07: Metastatic breast cancer resistant to paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and further anthracycline therapy is contraindicated" ;
  onco:related <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/capecitabine-temozolomide/>, <https://onco.cc/drugs/uridine-triacetate/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/her2-positive-breast-brain-metastases/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/rapido/>, <https://onco.cc/trials/nct04854668/>, <https://onco.cc/trials/nct06435429/>, <https://onco.cc/trials/nct07412613/>, <https://onco.cc/trials/nct06118333/>, <https://onco.cc/trials/nct04430738/>, <https://onco.cc/trials/nct07805551/>, <https://onco.cc/trials/nct05009069/>, <https://onco.cc/trials/nct07432295/>, <https://onco.cc/trials/nct05126719/>, <https://onco.cc/trials/nct06324357/>, <https://onco.cc/trials/nct05382442/>, <https://onco.cc/trials/nct02955940/>, <https://onco.cc/trials/nct05093907/>, <https://onco.cc/trials/nct06493760/>, <https://onco.cc/trials/nct05489211/>, <https://onco.cc/trials/nct06081959/>, <https://onco.cc/trials/nct06393374/>, <https://onco.cc/trials/nct05300269/>, <https://onco.cc/trials/nct07554521/>, <https://onco.cc/trials/nct05980481/>, <https://onco.cc/trials/nct06202261/>, <https://onco.cc/trials/nct03899155/>, <https://onco.cc/trials/nct05702229/>, <https://onco.cc/trials/nct06469944/>, <https://onco.cc/trials/nct06155383/>, <https://onco.cc/trials/nct05814354/>, <https://onco.cc/trials/nct06901531/>, <https://onco.cc/trials/nct07331155/>, <https://onco.cc/trials/nct06942234/>, <https://onco.cc/trials/nct05785741/>, <https://onco.cc/trials/nct06247956/>, <https://onco.cc/trials/nct06312176/>, <https://onco.cc/trials/nct06764875/>, <https://onco.cc/trials/nct05840211/>, <https://onco.cc/trials/nct06343948/>, <https://onco.cc/trials/nct06771622/>, <https://onco.cc/trials/nct06568692/>, <https://onco.cc/trials/nct05700084/>, <https://onco.cc/trials/nct07060807/>, <https://onco.cc/trials/nct07056777/>, <https://onco.cc/trials/nct05934331/>, <https://onco.cc/trials/nct06109779/>, <https://onco.cc/trials/nct05144854/>, <https://onco.cc/trials/nct07007559/>, <https://onco.cc/trials/nct06764940/>, <https://onco.cc/trials/nct07582315/>, <https://onco.cc/trials/nct07606599/>, <https://onco.cc/trials/nct07431281/>, <https://onco.cc/trials/nct04895358/>, <https://onco.cc/trials/nct06957886/>, <https://onco.cc/trials/nct07315750/>, <https://onco.cc/trials/nct04379596/>, <https://onco.cc/trials/nct07069712/>, <https://onco.cc/trials/nct06247995/>, <https://onco.cc/trials/nct07679360/>, <https://onco.cc/trials/nct06279364/>, <https://onco.cc/trials/spotlight-glow/>, <https://onco.cc/trials/nct04721977/>, <https://onco.cc/trials/nct07390383/>, <https://onco.cc/trials/nct06313983/>, <https://onco.cc/trials/nct06825494/>, <https://onco.cc/trials/nct07283367/>, <https://onco.cc/trials/nct07140393/>, <https://onco.cc/trials/nct06703177/>, <https://onco.cc/trials/nct04550260/>, <https://onco.cc/trials/nct07648914/>, <https://onco.cc/trials/nct07071337/>, <https://onco.cc/trials/nct06741644/>, <https://onco.cc/trials/nct04639986/>, <https://onco.cc/trials/nct05671822/>, <https://onco.cc/trials/nct06256328/>, <https://onco.cc/trials/nct04919226/>, <https://onco.cc/trials/nct04725994/>, <https://onco.cc/trials/create-x/>, <https://onco.cc/trials/sysucc-001/>, <https://onco.cc/trials/geicam-ciboma/>, <https://onco.cc/trials/ea1131/>, <https://onco.cc/trials/bre12-158/>, <https://onco.cc/trials/ascent-05/>, <https://onco.cc/trials/tropion-breast03/>, <https://onco.cc/trials/keynote-119/>, <https://onco.cc/trials/espac-4/>, <https://onco.cc/trials/espac-5/>, <https://onco.cc/trials/scalop/>, <https://onco.cc/trials/scalop-2/>, <https://onco.cc/trials/lap07/> .